24/7 Market News Snapshot 04 September, 2025 – Purple Biotech Ltd. American Depositary Shares (NASDAQ:PPBT)
DENVER, Colo., 04 September, 2025 (www.247marketnews.com) – (NASDAQ:PPBT) are discussed in this article.
Exciting developments are underway for Purple Biotech Ltd. (PPBT), as the clinical-stage biotechnology company has experienced significant market movement with its stock price soaring to $2.105 during pre-market trading, reflecting a remarkable increase of 48.24% from the previous close of $1.420. This surge indicates strong investor enthusiasm, with the trading volume reaching 2.77 million shares, highlighting confidence in the company’s innovative direction.
In tandem with its impressive market performance, Purple Biotech has announced groundbreaking findings in its collaboration with Dr. Amir Horowitz, Principal Investigator at a renowned cancer research institute. The research focuses on IM1240, a tri-specific antibody developed to address treatment-resistant cancers. Recent laboratory data reveals that IM1240 has effectively induced tumor cell death in biopsies from patients with head and neck cancers that have resisted conventional therapies. The mechanism shows a unique synergistic action between the antibody’s CD3 and NKG2A-engaging elements, proposing a potentially transformative approach for addressing non-small cell lung and bladder cancers.
Gil Efron, CEO of Purple Biotech, emphasized the critical role of Dr. Horowitz’s expertise in cancer immunology in assessing IM1240’s effects on patient-derived tumor biopsies. The findings indicate that targeting NKG2A may enable a selective checkpoint inhibition strategy that bears less risk compared to existing immunotherapies. The correlation identified between NKG2A and tumor-associated antigens within the tumor microenvironment is pivotal for future developments in cancer treatment.
Dr. Horowitz presented these promising findings at a prestigious annual meeting, which captured the attention of the oncology community. As Purple Biotech aims to advance to first-in-human clinical trials, the company plans to submit an Investigational New Drug (IND) application for IM1240 in 2026, underscoring its dedication to pioneering advancements in cancer therapy and improving patient care in the face of aggressive forms of the disease.